MONTEREY, Calif. — OC-01 nasal spray showed a significant decrease in the signs and symptoms of dry eye in patients with autoimmune disease and associated dry eye disease.
The study was presented in a poster by Julie Schallhorn, MD, MS, and co-authors at the Women in Ophthalmology 2022 Summer Symposium. A subpopulation of patients with autoimmune disease (AID) was selected from the ONSET-1 and ONSET-2 studies that previously evaluated the safety and efficacy of OC-01 (varenicline solution, Oyster Point Pharma) nasal spray in dry eye disease (DED). In the two (Read more...)